These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

327 related articles for article (PubMed ID: 21747082)

  • 21. Comparative efficacy of nilotinib and dasatinib in newly diagnosed chronic myeloid leukemia: a matching-adjusted indirect comparison of randomized trials.
    Signorovitch JE; Wu EQ; Betts KA; Parikh K; Kantor E; Guo A; Bollu VK; Williams D; Wei LJ; DeAngelo DJ
    Curr Med Res Opin; 2011 Jun; 27(6):1263-71. PubMed ID: 21524239
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Navigating the road toward optimal initial therapy for chronic myeloid leukemia.
    Okimoto RA; Van Etten RA
    Curr Opin Hematol; 2011 Mar; 18(2):89-97. PubMed ID: 21252655
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparing nilotinib with dasatinib as second-line therapies in patients with chronic myelogenous leukemia resistant or intolerant to imatinib -- a retrospective chart review analysis.
    Griffin JD; Guerin A; Chen L; Macalalad AR; Luo J; Ionescu-Ittu R; Wu EQ
    Curr Med Res Opin; 2013 Jun; 29(6):623-31. PubMed ID: 23517347
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.
    Kantarjian H; Shah NP; Hochhaus A; Cortes J; Shah S; Ayala M; Moiraghi B; Shen Z; Mayer J; Pasquini R; Nakamae H; Huguet F; Boqué C; Chuah C; Bleickardt E; Bradley-Garelik MB; Zhu C; Szatrowski T; Shapiro D; Baccarani M
    N Engl J Med; 2010 Jun; 362(24):2260-70. PubMed ID: 20525995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea.
    Whiteley J; Iyer S; Candrilli SD; Kaye JA
    Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).
    Hjorth-Hansen H; Stenke L; Söderlund S; Dreimane A; Ehrencrona H; Gedde-Dahl T; Gjertsen BT; Höglund M; Koskenvesa P; Lotfi K; Majeed W; Markevärn B; Ohm L; Olsson-Strömberg U; Remes K; Suominen M; Simonsson B; Porkka K; Mustjoki S; Richter J;
    Eur J Haematol; 2015 Mar; 94(3):243-50. PubMed ID: 25082346
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia: systematic reviews and economic analyses.
    Pavey T; Hoyle M; Ciani O; Crathorne L; Jones-Hughes T; Cooper C; Osipenko L; Venkatachalam M; Rudin C; Ukoumunne O; Garside R; Anderson R
    Health Technol Assess; 2012; 16(42):iii-iv, 1-277. PubMed ID: 23134589
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Current therapy of chronic myeloid leukemia].
    Koskela H; Koskenvesa P; Mustjoki S; Porkka K
    Duodecim; 2012; 128(6):579-88. PubMed ID: 22506320
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Developmental Therapeutics Consortium report on study design effects on trial outcomes in chronic myeloid leukaemia.
    Giles F; Mahon FX; Gjertsen B; Swords R; Labar B; Turkina A; Rosti G
    Eur J Clin Invest; 2012 Sep; 42(9):1016-26. PubMed ID: 22548456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcome of treatment of chronic myeloid leukemia with second-generation tyrosine kinase inhibitors after imatinib failure.
    Cornelison AM; Kantarjian H; Cortes J; Jabbour E
    Clin Lymphoma Myeloma Leuk; 2011 Jun; 11 Suppl 1(0 1):S101-10. PubMed ID: 22035738
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib.
    Hochhaus A; Baccarani M; Deininger M; Apperley JF; Lipton JH; Goldberg SL; Corm S; Shah NP; Cervantes F; Silver RT; Niederwieser D; Stone RM; Dombret H; Larson RA; Roy L; Hughes T; Müller MC; Ezzeddine R; Countouriotis AM; Kantarjian HM
    Leukemia; 2008 Jun; 22(6):1200-6. PubMed ID: 18401416
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapy options in imatinib failures.
    Ramirez P; DiPersio JF
    Oncologist; 2008 Apr; 13(4):424-34. PubMed ID: 18448557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of dasatinib and nilotinib in imatinib-resistant chronic myeloid leukemia: translating preclinical findings to clinical practice.
    DeAngelo DJ; Attar EC
    Leuk Lymphoma; 2010 Mar; 51(3):363-75. PubMed ID: 20038231
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment with dasatinib or nilotinib in chronic myeloid leukemia patients who failed to respond to two previously administered tyrosine kinase inhibitors--a single center experience.
    Ribeiro BF; Miranda EC; Albuquerque DM; Delamain MT; Oliveira-Duarte G; Almeida MH; Vergílio B; Silveira RA; Oliveira-Duarte V; Lorand-Metze I; De Souza CA; Pagnano KB
    Clinics (Sao Paulo); 2015 Aug; 70(8):550-5. PubMed ID: 26247667
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimated glomerular filtration rate changes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.
    Yilmaz M; Lahoti A; O'Brien S; Nogueras-González GM; Burger J; Ferrajoli A; Borthakur G; Ravandi F; Pierce S; Jabbour E; Kantarjian H; Cortes JE
    Cancer; 2015 Nov; 121(21):3894-904. PubMed ID: 26217876
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.
    Marcé S; Zamora L; Cabezón M; Xicoy B; Boqué C; Fernández C; Grau J; Navarro JT; Fernández de Sevilla A; Ribera JM; Feliu E; Millá F;
    Med Clin (Barc); 2013 Aug; 141(3):95-9. PubMed ID: 23433665
    [TBL] [Abstract][Full Text] [Related]  

  • 37. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib.
    Wei G; Rafiyath S; Liu D
    J Hematol Oncol; 2010 Nov; 3():47. PubMed ID: 21108851
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome with dasatinib after imatinib failure in chronic-phase chronic myeloid leukemia: follow-up of a phase 3 study.
    Shah NP; Guilhot F; Cortes JE; Schiffer CA; le Coutre P; Brümmendorf TH; Kantarjian HM; Hochhaus A; Rousselot P; Mohamed H; Healey D; Cunningham M; Saglio G
    Blood; 2014 Apr; 123(15):2317-24. PubMed ID: 24569263
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
    Henk HJ; Woloj M; Shapiro M; Whiteley J
    Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dasatinib early intervention after cytogenetic or hematologic resistance to imatinib in patients with chronic myeloid leukemia.
    Quintás-Cardama A; Cortes JE; O'Brien S; Ravandi F; Borthakur G; Liu D; Bleickardt E; Chen TT; Kantarjian HM
    Cancer; 2009 Jul; 115(13):2912-21. PubMed ID: 19402171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.